Bài viết

References - [Clinical Application of “Curcumin”, a Multi-Functional Substance]

References - [Clinical Application of “Curcumin”, a Multi-Functional Substance]

Viết bởi ReadyQ / 0 bình luận

Clinical Application of “Curcumin”, a Multi-Functional Substance


We would like to express our deep gratitude to Drs. Koji Hasegawa, Hiroki Sasaki, Yoshihiko Otsuka, and Tadashi Hashimoto, who provided useful comments. This work was supported in part by research grants from the Japan Society for the Promotion of Sciences (JSPS) and the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.

Conflict of interest statement:

The authors declare no financial or other conflicts of interest in the writing of this paper.


1) Anand P, Kunnumakkara AB, Newman RA, et al: Bioavailability of curcumin: problems and promises. Mol Pharm 4(6); 807-18: 2007

2) Aggarwal BB, Surh YJ, Shihsodia S (Ed).: The molecular targets and therapeutic uses of curcumin in health and disease. Adv Exp Med Biol 595; 8: 2007

3) Kanai M, Imaizumi A, Otsuka Y, et al: Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers. Cancer Chemother Pharmacol. in press

4) Sasaki H, Sunagawa Y, Takahashi K, et al: Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 34(5); 660-5: 2011

5) Rabe JH, Mamelak AJ, McElgunn PJ, et al: Photoaging: mechanisms and repair. J Am Acad Dermatol 55(1): 1-19: 2006

6) Morimoto T, Sunagawa Y, Fujita M, et al: Novel heart failure therapy targeting transcriptional pathway in cardiomyocytes by a natural compound, curcumin. Circ J 74(6) ; 1059-66: 2010

7) Morimoto T, Hasegawa K, Kaburagi S, et al: Phosphorylation of GATA-4 is involved in α1-adrenergic agonist-responsive transcription of the endothelin-1 gene in cardiac myocytes. J Biol Chem 275; 13721-6: 2000

8) Morimoto T, Hasegawa K, Kaburagi S, al: Calcineurin- GATA4 pathway is involved in β-adrenergic agonist-responsive endothelin-1 transcription in cardiac myocytes. J Biol Chem 276(37); 34983-9: 2001

9) Morimoto T, Hasegawa K, Kaburagi S, et al: GATA-5 is involved in leukemia inhibitory factor-responsive transcription of the β-myosin heavy chain gene in cardiac myocytes. J Biol Chem 274; 12811-8: 1999

10) Yanazume T, Hasegawa K, Wada H, et al: Rho/ROCK pathway contributes to the activation of extracellular signal-regulated kinase/GATA-4 during myocardial cell hypertrophy. J Biol Chem 277(10); 8618-25: 2002

11) Hirai M, Ono K, Morimoto T, et al: FOG-2 competes with GATA-4 for a transcriptional coactivator p300 and represses hypertrophic responses in cardiac myocytes. J Biol Chem 279(36); 37640-50: 2004

12) Yanazume T, Hasegawa K, Morimoto T, et al: Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol Cell Biol 23 ; 3593-606: 2003

13) Kakita T, Hasegawa K, Morimoto T, et al: p300 protein as a coactivator of GATA-5 in the transcription of cardiac-restricted atrial natriuretic factor gene. J Biol Chem 274; 34096-102: 1999

14) Takaya T, Kawamura T, Morimoto T, et al: Identification of p300- targeted acetylated residues in GATA-4 during hypertrophic responses in cardiac myocytes. J Biol Chem 283(15); 9828-35: 2008

15) Miyamoto S, Kawamura T, Morimoto T, et al: Histone acetyltransferase activity of p300 is required for the promotion of left ventricular remodeling following myocardial infarction in adult mice in vivo Circulation 113; 679-90: 2006

16) Balasubramanyam K, Varier RA, Altaf M, et al: Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 279; 51163-71: 2004

17) Morimoto T, Sunagawa Y, Kawamura T, et al: Curcumin, an inhibitor of p300 histone acetyltransferase activity, prevents the development of heart failure. J Clin Invest 118; 868-78: 2008

18) Sunagawa Y, Morimoto T, Wada H, et al: A natural p300- specific histone acetyltransferase inhibitor, curcumin, in addition to angiotensin-converting enzyme inhibitor, exerts beneficial effects on left ventricular systolic function after myocardial infarction in rats. Circ J 75(9); 2151-9: 2011

19) Sunagawa Y, Wada H, Sasaki H, et al: A novel drug delivery system of oral curcumin markedly improves efficacy of treatment  

20) Aggarwal BB, Sundaram C, Malani N, et al: Curcumin: the Indian solid gold. Adv Exp Med Biol 595; 1-75: 2007

21) Shishodia S, Chaturvedi MM, Aggarwal BB: Role of curcumin in cancer therapy. Curr Probl Cancer 31; 243-305: 2007

22) Strimpakos AS, Sharma RA: Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10; 511-45: 2008

23) Aggarwal BB, Takada Y, Oommen OV. From chemoprevention to chemotherapy: common targets and common goals. Expert Opin Investig Drugs 13(10): 1327-38: 2004

24) Dhillon N, Aggarwal BB, Newman RA, et al: Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14; 4491-9: 2008

25) Kanai M, Yoshimura K, Asada M, et al: A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 68; 157-64: 2011

26) Shoba G, Joy D, Joseph T, et al: Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64; 353-6: 1998

27) Cheng AL, Hsu CH, Lin JK, et al: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21; 2895-900: 2001

28) Sharma RA, Euden SA, Platton SL, et al: Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10: 6847-54, 2004

29) Lao CD, Ruffin MTt, Normolle D, et al: Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6; 10: 2006

30) Garcea G, Berry DP, Jones DJ, et al: Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14; 120-5: 2005

31) Vareed SK, Kakarala M, Ruffin MT, et al: Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev 17; 1411-7: 2008

32) Tanaka H, Dinenno FA, Monahan KD, et al: Aging, habital exercise, and dynamic arterial compliance. Circulation 102; 1270-1275: 2000

33) Iemitsu M, Maeda S, Otsuki T, et al: Polymorphism in endothelin-related genes limits exercise-induced decreases in arterial stiffness in older subjects. Hypertension 47; 928-936: 2006

34) Kakiyama T, Sugawara J, Murakami H, et al: Effects of short- term endurance training on aortic distensibility in young males. Med Sci Sports Exerc 37; 267-271: 2005

35) Yoshizawa M, Maeda S, Miyaki A, et al: Additive beneficial effects of lactotripeptide and aerobic exercise on arterial compliance in postmenopausal women. Am J Physiol Heart Circ Physiol 297; H1899-H1903: 2009

36) Maeda S, Tanabe T, Otsuki T, et al: Acute exercise increases systemic arterial compliance after 6-month exercise training in older women. Hypertens Res 31; 377-381: 2008

37) Miyaki A, Maeda S, Yoshizawa M, et al: Effect of habitual aerobic exercise on body weight and arterial function in overweight and obese men. Am J Cardiol 104; 823-828: 2009

38) Maeda S, Sugawara J, Yoshizawa M, et al: Involvement of endothelin-1 in habitual exercise-induced increase in arterial compliance. Acta Physiol 196; 223-229: 2009

39) Miyaki A, Maeda S, Yoshizawa M, et al: Effect of weight reduction with dietary intervention on arterial distensibility and endothelial function in obese men. Angiology 60; 351-357: 2009

40) Tanaka H, Safar ME.: Influence of lifestyle modification on arterial stiffness and wave reflections. Am J Hypertens 18; 137- 144: 2005

41) Avolio AP, Deng FQ, Li WQ, et al: Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: comparison between urban and rural communities in China. Circulation 71; 202-210: 1985

42) Seals DR, Tanaka H, Clevenger CM, et al: Blood pressure reductions with exercise and sodium restriction in postmenopausal women with elevated systolic pressure: role of arterial stiffness. J Am Coll Cardiol 38; 506-513: 2001

43) Hamazaki T, Urakaze M, Sawazaki S, et al: Comparison of pulse wave velocity of the aorta between inhabitants of fishing and farming villages in Japan. Atherosclerosis 73; 157-160: 1988.

Viết bình luận của bạn:

Các tin khác


Số lượng:

Tổng tiền: